Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) FCF Margin (2016 - 2025)

Regen BioPharma (RGBP) has disclosed FCF Margin for 11 consecutive years, with 269.52% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 7965.0% to 269.52% in Q3 2025 year-over-year; TTM through Dec 2025 was 290.23%, a 2324.0% increase, with the full-year FY2025 number at 162.15%, up 15554.0% from a year prior.
  • FCF Margin was 269.52% for Q3 2025 at Regen BioPharma, down from 94.77% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 58.75% in Q3 2021 to a low of 882.22% in Q4 2021.
  • A 5-year average of 238.74% and a median of 187.48% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: soared 84915bps in 2022, then tumbled -57177bps in 2024.
  • Regen BioPharma's FCF Margin stood at 882.22% in 2021, then skyrocketed by 96bps to 33.07% in 2022, then plummeted by -731bps to 274.84% in 2023, then soared by 59bps to 112.38% in 2024, then tumbled by -140bps to 269.52% in 2025.
  • Per Business Quant, the three most recent readings for RGBP's FCF Margin are 269.52% (Q3 2025), 94.77% (Q2 2025), and 171.39% (Q1 2025).